WFG Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

WFG Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$13K	Buy	84 +11	+15%	+$1.68K	﹤0.01%	1059
2017 Q1	$11K	Sell	73 -11	-13%	-$1.43K	﹤0.01%	1042
2016 Q4	$9K	Buy	84 +11	+15%	+$1.23K	﹤0.01%	1137
2016 Q3	$9K	Hold	73	–	–	﹤0.01%	1160
2016 Q2	$10K	Sell	73 -100	-58%	-$14.7K	﹤0.01%	1096
2016 Q1	$23K	Buy	173 +100	+137%	+$12.4K	0.01%	852
2015 Q4	$10K	Hold	73	–	–	﹤0.01%	1078
2015 Q3	$10K	Hold	73	–	–	﹤0.01%	1085
2015 Q2	$13K	Hold	73	–	–	﹤0.01%	1107
2015 Q1	$13K	Sell	73 -100	-58%	-$17.2K	﹤0.01%	1124
2014 Q4	$28K	Buy	+173	New	+$28.7K	0.01%	1110

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

WFG Advisors's JAZZ Position: Q2 2017 in Review

WFG Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 15% in Q2 2017, buying an estimated $1.68K and bringing the position to 84 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

WFG Advisors first reported a position in JAZZ in Q4 2014 and has held it in 11 quarters since. The position peaked at $28K in Q4 2014. 319 funds tracked by Wall St. Rank hold JAZZ as of Q2 2017.

WFG Advisors held 84 shares of Jazz Pharmaceuticals worth $13K as of Q2 2017.
WFG Advisors bought 11 Jazz Pharmaceuticals shares in Q2 2017, an estimated $1.68K.
Jazz Pharmaceuticals made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1059 holding.
WFG Advisors first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 11 quarters since.
WFG Advisors's Jazz Pharmaceuticals position peaked at $28K in Q4 2014.
319 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.